64 These findings raise the

possibility that the benefit of phosphate binders may extend Selleck LDK378 beyond lowering phosphate alone, and could be mediated through a decrease in FGF-23 levels. The impact of renal transplantation on FGF-23 levels has also been studied. FGF-23 levels are reported to remain elevated in the first few months post-renal transplantation compared with matched controls with a similar eGFR; however, this effect diminishes after 12 months.65–67 High FGF-23 prior to transplantation is independently associated with post-transplant hypophosphatemia and low calcitriol.66 Excess FGF-23, in addition to elevated PTH levels and calcineurin inhibitors, may therefore be another mechanism for post-transplantation hypophosphatemia. In a small study of find more 10 transplant recipients with persisting SHPT, cinacalcet was associated

with a significant decrease in PTH and FGF-23 levels, although the reduction in phosphaturia was more strongly correlated with a reduction in PTH levels.68 FGF-23 has the potential to influence how and when we treat patients with CKD-MBD. The temptation to integrate FGF-23 measurements into current clinical practice should be cautioned by the many questions that still remain unanswered. The exact role of FGF-23, the determination of its ‘normal’ range and variation, and the association of FGF-23 with dietary phosphate intake and mediators that affect its secretion all need to be further delineated. It is clear that FGF-23 plays a significant

role in mineral metabolism and mediates changes that lead to SHPT in CKD; however, we have a fragmented understanding of the factors that mediate the elevation of FGF-23 in CKD. The effects of bone-derived FGF-23 regulators and local tissue phosphate and calcitriol concentrations on FGF-23 levels are of particular interest. With the recognition that the activity of extra-renal 1α-hydroxylase activity is important in CKD patients, the need to understand the effects of FGF-23 on this enzyme is paramount. The plethora of studies linking FGF-23 with various biochemical and clinical outcomes Selleck Enzalutamide are largely observational. There still remains a paucity of data outlining FGF-23 measurements in the various CKD subgroups, and prospective clinical studies are lacking. The postulated direct, toxic effects of FGF-23 on tissues, in particular the CV system, remain largely theoretical. The association between FGF-23 and phosphate also raises the question of treating phosphate levels within the currently accepted ‘normal range’. The clinical utility of FGF-23 in CKD may be as a diagnostic and prognostic biomarker; however, its use as a ‘universal’ therapeutic target for the various CKD-MBD treatments needs further evaluation. The use of FGF-23 in this capacity may parallel some of the controversies associated with PTH measurements.